Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer .
Filed returns
56
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Pfizer | Health | Discussion on the EU Biotech Act, access to medicines, innovation, and Ireland's life sciences policy environment, including opportunities to strengthen research, development, manufacturing, and the competitiveness of… (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Ireland’s National Life Sciences Strategy (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicine (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| Sep–Dec 2025 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 19 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 9 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV protection for infants and older adults (Public policy or programme) | 9 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Health | Treatment of Amyloidosis and ATTR-CM M (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV protection for infants and older adults (Public policy or programme) | 6 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 7 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | Health | Access to an antiviral medication for the treatment of COVID-19 (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 15 | On lobbying.ie |
| May–Aug 2024 | Pfizer | Health | Digital Policy and the Life Science Industry (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2024 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicines and vaccines (Matters involving public funds) | 1 | On lobbying.ie |
| Jan–Apr 2024 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicines and vaccines (Matters involving public funds) | 14 | On lobbying.ie |
| Sep–Dec 2023 | Pfizer | Health | Exchange about the burden of sickle-cell disease in Europe and the Pfizer-supported call to action Shaping the Change for Sickle Cell Disease Patients in Europe and Beyond. (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2023 | Pfizer | Health | Migraine Summit (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2023 | Pfizer | Health | Ireland's medicine reimbursement system and Budget funding for new medicines (Matters involving public funds) | 9 | On lobbying.ie |
| May–Aug 2023 | Pfizer | Health | Ireland's reimbursement system and funding for new medicines (Public policy or programme) | 6 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | Health | Ireland's pricing and reimbursement system and funding for new medicines (Public policy or programme) | 14 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Health | Pfizer anti-viral COVID-19 treatment and COVID-19 cases (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Health | COVID-19 vaccination programme (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Health | Pfizer COVID-19 anti-viral treatment (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Health | PMB re orphan medicines, Health (Pricing and Supply of Medical Goods) (Amendment) Bill 2021 (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2022 | Pfizer | Health | Update on Pfizer COVID 19 antiviral treatment and processes in ensuring availability of the treatment in Ireland (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2022 | Pfizer | Health | PMB in relation to reimbursement of orphan medicines Health (Pricing and Supply of Medical Goods) (Amendment) Bill 2021 (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Health | Agreement on Pricing and Supply of Medicines 2021 - 2025 (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Health | COVID-19 vaccination programme (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Health | Pfizer has an investigational COVID-19 treatment, a protease inhibitor which subject to clinical trials and regulatory approvals could play a complementary role to vaccination in helping to manage COVID-19 (Matters involving public funds) | 5 | On lobbying.ie |
| May–Aug 2021 | Pfizer | Health | Supply of Pfizer COVID-19 vaccine including Ireland volumes; expansion of manufacturing capacity to include Grange Castle site and Pfizer colleague vaccination programme (Public policy or programme) | 8 | On lobbying.ie |
| May–Aug 2021 | Pfizer | Health | Outline Ireland's medicine reimbursement system and timelines compared with other countries (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Health | Highlight Ireland's slowness in reimbursing new medicines for Irish patients compared with other EU countries (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Health | Updates in relation to Pfizer COVID 19 vaccine including global production, Ireland volumes and company colleague vaccination programme (Matters involving public funds) | 10 | On lobbying.ie |
| Sep–Dec 2020 | Pfizer | Health | Highlight Ireland's slowness in reimbursing innovative medicines compared to other European countries and outline factors contributing to this (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2020 | Pfizer | Health | Discussions in relation to Pfizer/BioNtech progress in development of a vaccine for COVID 19 (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Health | Highlighted discussions on extension of industry Supply Agreement and the importance of ensuring expenditure is efficently managed to ensure Irish patients can access innovative medicines; welcomed plans to progress the… (Public policy or programme) | 28 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Health | Provided information about Pfizer's research into a COVID-19 vaccine, meeting sought with MoH/DoH. (Public policy or programme) | 29 | On lobbying.ie |
| May–Aug 2019 | Pfizer | Health | Ireland has become one of the slowest countries in Europe to reimburse innovative medicines for patients, now ranking 16th out of 26th according to EFPIA. (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2018 | Pfizer | Health | Ireland has become one of the slowest countries in Europe to reimburse innovative medicines for patients, now ranking 16th out of 26th according to EFPIA. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2018 | Pfizer | Health | Pfizer is seeking reimbursement for a new treatment for metatastic breast cancer which is reimbursed in the majority of EU countries but not yet in Ireland. Ireland has become one of the slowest countries in Europe to… (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Pfizer is seeking reimbursement for a new treatment for metatastic breast cancer which is reimbursed in the majority of EU countries but not yet in Ireland. Ireland has become one of the slowest countries in Europe to… (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Science Foundation Ireland has a research centre, INNATE which has been approved in principle but requires funding. The infrastructure and focus intended by INNATE would help upskill scientists and help translate early… (Matters involving public funds) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | The Anti-Microbial Resistance Plan was due for publication in September 2017. The 3-year Plan covers the use of anti-microbial medicines in animal health and agriculture, and human health - taking a 'One Health'… (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Pfizer launched 'MBC: A Call to Action' to highlight the unmet needs of metastatic breast cancer patients. MBC is an advanced form of breast cancer where early detection does not improve survival. Even if diagnosed with… (Public policy or programme) | 14 | On lobbying.ie |
| May–Aug 2017 | Pfizer | Health | Ireland has now become one of the slowest countries in Europe to reimburse innovative medicines for patients. HTA assessment is prolonged and decisions after HTA are exceptionally slow with the majority of medicines… (Public policy or programme) | 12 | On lobbying.ie |
| May–Aug 2017 | Pfizer | Health | Pfizer is seeking reimbursement for a new treatment for metastatic breast cancer. Metastatic breast cancer is an advanced form of breast cancer where early detection unfortunately does not improve survival. Even if… (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2017 | Pfizer | Health | A Supply Agreement was negotiated in 2016 between the pharmaceutical industry and the state which provides 785m in savings over four years, ensures Irish on patent medicine prices are in line with 14 other EU countries… (Public policy or programme) | 7 | On lobbying.ie |
| Jan–Apr 2017 | Pfizer | Health | Pfizer is seeking reimbursement for a new treatment for metastatic breast cancer. Metastatic breast cancer is an advanced form of breast cancer where early detection unfortunately does not improve survival. Even if… (Matters involving public funds) | 8 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 56 | 100.0% |